Received Mar 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y009982 | — |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | Y005457 | — |
No Side effects or symptoms reported.; HCP called to report PROQUAD and PEDVAX HIB were mixed and administered to one patient.; This spontaneous report was received from a registered nurse and refers to 19-months-old male patient The patient's medical history, current conditions and concomitant therapies were not reported. On 13-MAR-2025, the patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live recombinant human albumin (rHA) (PROQUAD), (lot #Y009982 who had been verified to be a valid lot number, expiration date reported and validated as 24-NOV-2025); and Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB), (lot #Y005457 who had been verified to be a valid lot number, expiration date reported and validated as 06-NOV-2026) (exact doses, anatomical routes of administration, lot number and expiration date were not reported), both vaccines administered for prophylaxis. It was reported that the vaccines were mixed and administered to patient (product preparation issue). No additional adverse events.
Sterile diluent